Multiplexing Brings HTS to Higher Level

July 15, 2011

Multiplex assays are based on single analyte tests or low-to-midplex procedures that typically predate the rise of their multiplex versions. They may include vast numbers of analytes in a single assay and require specialized technologies or miniaturization to achieve a higher degree of parallelization.

Read the full article

Small Molecular Simplicity Gives Them Staying Power

June 15, 2011

There is a profound association between cancer and inflammatory processes, according to Raffaella Sordella, Ph.D., assistant professor at Cold Spring Harbor Laboratory. Dr. Sordella was a keynote speaker at CHI’s recent conference on drug discovery chemistry.

Discussions at the meeting about small molecule approaches to anti-inflammatory therapies devoted considerable time to the link between malignancy and inflammation.

Read the full article

Shaking Up Downstream Processing

April 1, 2011

Liverpool is best known as the scruffy British industrial city that gave the Beatles their start back in the 60s, but it is recognized today for reinventing its image as a home to an expanding biotech presence. SAFC (www.safcglobal.com) and Sartorius Stedim (www.sartorius-stedim.com) recent “Downstream Processing Day” seminar was held in the city and brought together investigators from a number of companies, many with facilities at the Liverpool Science Park.

Read the full article

Cancer Marker Pursuit Heats Up

March 15, 2011

The search for cancer biomarkers has proven to be a long, frustrating, and mainly fruitless exercise. Despite the substantial investment, no new markers suitable for large-scale screening protocols have achieved FDA approval. Yet, improvements in investigative tools, as well as innovative computer analysis, offer hope that the situation may be changing, and newly characterized candidates may prove to be clinically useful.

Read the full article

Strategies to Advance mAb Production

March 1, 2011

While approval of new therapeutic antibodies has not progressed as rapidly as was forecast 10 years ago, new products are moving through the pipeline. As always, bioprocessing, critical to antibody manufacture, is a key factor in the cost and efficiency of production.

Interviews with company officials and researchers engaged in bioprocessing showed how novel approaches to these challenges are moving the industry forward.

Read the full article

Making Strides in Protein Characterization

February 1, 2011

The bioprocessing industry continues to transform and reinvent itself as a range of new technologies is introduced and adopted. The sequencing of the human genome has made available a wealth of targets for drug development, translating into a demand for appropriate biotherapeutics. Moreover, the expiration of patent protection for many biologics is fueling increasing interest in biosimilars.

Read the full article

Novel Methods Expedite Nucleic Acid Sample Prep

January 1, 2011

Recent developments in genomic identification using microarray technologies are infiltrating the fields of forensics, diagnostics, and sample identification. They include a combination of new hardware designs and innovative approaches to sample processing. In addition, microfluidics and miniaturization are emerging as key components of powerful new multiplexing platforms. Knowing how to reduce risks is vital to avoiding legal trouble in this still-emerging field.

Read the full article

About Us

Newport Biotechnology Consultants, founded in 2005, originally was aimed at providing writing expertise in the life sciences industry, with a specialization in molecular immunology. I drew upon my academic and industrial background to cover new developments and technologies in antibody therapies and related areas of biotechnology. These reviews were published in a number of trade journals, especially articles in Genetic Engineering and Biotechnology News (see articles). More recently I have expanded my writing into other fields, including emergency management, drug discovery, bioprocessing, environmental and sustainable technologies, micro- and nanotechnology and many other areas. I also am involved in regulatory issues. I am Chair of the Meridian Bioscience Institutional Biosafety Committee, and I am a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee (see consulting services). Both IBCs review research protocols dealing with the use of recombinant DNA. Finally, I have consulted for a number of companies on laboratory design, business plan evaluation and regulatory questions.

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin